Theragenics Corporation (TGX)

[surf1944]

7:11AM Theragenics receives FDA clearance to market Galt VTI valved tearaway introducer (TGX) 1.72 : Co has received FDA 510(k) clearance to market its Galt VTI valved tearaway introducer. Introducers are utilized for vascular access, with the Galt VTI expected to be utilized primarily for placing catheters. The Galt VTI is expected to be launched in the second half of 2012, with revenue in the range of $300,000 expected in this calendar year based on indications of interest from our customer base. Within twelve months of launch, co expects the Galt VTI to generate annualized revenue of $1 million to $2 million, with gross profit margins higher than currently being realized in the Company's Surgical Products segment.